• news
    • Press releases
    • Blog
    • Media Coverage
    • Event
  • Documents
  • About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • knowledgehub
    • what is KI EIS fund?
  • Contact

o2h-ventures

  • news
    • Press releases
    • Blog
    • Media Coverage
    • Event
  • Documents
  • About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • knowledgehub
    • what is KI EIS fund?
  • Contact

Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more

June23 updates – o2h Ventures award finalists, portfolio company news and more…
June23 updates – o2h Ventures award finalists, portfolio company news and more…
Jun 21 2023

It has been an exciting start to the summer, as we have seen o2h Ventures shortlisted for two awards this year. Firstly, the UKBAA award for “Best Seed VC of the Year’ and secondly, the EISA award for ‘Impact Investing’. It’s great to have some recognition for the efforts we put into both selecting our investments and supporting them. o2h Ventures has made 30 investments since inception and is either the first investor or lead investor in ~50% of these deals. As Turbine closed their ‘€20M’ Series A investment last quarter, we are seeing other companies from our portfolio to closing similar size rounds. Watch this space for more updates.
The latest data from HMRC suggests that the S/EIS scheme continues to provide significant support to the UK’s early-stage ecosystem. From 2021-22, an impressive 4,480 companies raised a staggering £2,305 million through the EIS schemes, and additionally, 2,270 companies secured funds totaling £205 million through the SEIS schemes.

o2h Portfolio Highlights:

  • Tay Therapeutics, a spinout from the University of Dundee has secured its second licensing deal with VYNE Therapeutics Inc. The agreement calls for an initial payment and subsequent instalments totalling up to $65 million.
  • PharmEnable, a Cambridge University spinout successfully closed a $7.5 million pre-Series A funding, which was led by MP Healthcare Venture Management (MPH), the venture arm of Mitsubishi Tanabe Pharma Group.
  • BiVictriX Therapeutics (AIM: BVX), based in Manchester, an Antibody Drug Conjugate platform company targeting Cancer has nominated clinical candidates for its lead programme.
  • Alevin Therapeutics, a University of Nottingham spin-out focused on integrin inhibitors as novel treatments for Idiopathic Pulmonary Fibrosis has been shortlisted for EISA Awards in the category Best SEIS Investee Company.
  • Neurocentrx Pharma Ltd, an Edinburgh-based psychedelics company developing oral Ketamine for mood disorders and other neurological diseases, announced initial positive results results from its Phase I clinical trial. The data indicate that Keticap® is safe and well tolerated up to the highest dose level.
  • Cardiatec Biosciences, a Cambridge University spinout won “The One to Watch” award at the Cambridge Independent Science and Technology Awards 2023. Several other o2h Ventures portfolio companies were shortlisted finalists for awards including Five Alarm Bio Limited, Alevin Therapeutics Ltd, Arecor Therapeutics plc, and Stemnovate Limited.

Have a look at our existing portfolio: o2hventures.com/portfolio.

SEIS Fund Open for Investment
The o2h Human Health SEIS Fund is open for investment, and applications for investment should be submitted by 30th June 2023.

o2h Ventures SEIS fund is OPEN for investment

Next SEIS investment in the works
Camgene Therapeutics, a new company that will target diseases of the ear, building upon the success of the COVID vaccines utilizing Lipid Nanoparticles (LNPs) in transporting mRNA which is used as a therapeutic agent.

ChaiTime Episodes
For those interested in learning more about SEIS and biotech investing, we have released two captivating episodes of o2h ChaiTime Webinar in May. o2h ChaiTime is a series of lively conversations with leaders and experts from biotech, tech, VC, and the wider community. Click to watch these episodes online…

o2h Chaitime Webinar on biotech and SEIS investing

If you would like to know more about our open funds, please visit here or send us a short note to invest@o2h.com and we will schedule a call accordingly.

Connect with us
  • linkedin
  • youtube
  • email
o2h-ventures
o2h-ventures
o2h Ventures Limited
Hauxton House,
The Mill SciTech Park,
Mill Lane, Hauxton
Cambridge
CB22 5HX
07341612481
invest@o2h.com
about
  • about us
  • team
  • portfolio
  • funds
insights and news
  • knowledge hub
  • press releases
  • blog
  • event
  • documents
connect with us
  • linkedin
  • youtube
  • email
Please refer to the relevant fund’s full risk warnings contained in their Information Memorandums.
Your capital is at risk. Investing in early stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. o2h Ventures’ funds are targeted exclusively at sophisticated or high net worth investors who understand these risks and make their own investment decisions. Tax relief depends on an individual’s circumstances and may change in the future. In addition, the availability of tax relief depends on the company invested in maintaining its qualifying status. Past performance is not a reliable indicator of future performance. You should not rely on any past performance as a guarantee of future investment performance.
o2h ventures Limited is regulated and authorised by the Financial Conduct Authority (FRN 812245). Capital at risk, only suitable for high net worth and sophisticated investors
© 2025 o2h ventures
  • Privacy Policy
  • Blog
  • Contact us

Risk Information

Due to the potential for losses, the Financial Conduct Authority (FCA) considers this investment to be high risk

What are the key risks?

1 – You could lose all the money you invest

• If the business you invest in fails, you are likely to lose 100% of the money you invest. Most start-up businesses fail.

2 – You are unlikely to be protected if something goes wrong

• Protection from the Financial Services Compensation Scheme (FSCS), in relation to claims against failed regulated firms, does not cover poor investment performance. Try the FSCS investment protection checker here. (https://www.fscs.org.uk/check/investment-protection-checker)

• Protection from the Financial Ombudsman Service (FOS) does not cover poor investment performance. If you have a complaint against an FCA-regulated firm, FOS may be able to consider it. Learn more about FOS protection here. (https://www.financial-ombudsman.org.uk/consumers)

3 – You won’t get your money back quickly

• Even if the business you invest in is successful, it may take several years to get your money back. You are unlikely to be able to sell your investment early.

• The most likely way to get your money back is if the business is bought by another business or lists its shares on an exchange such as the London Stock Exchange. These events are not common.

• If you are investing in a start-up business, you should not expect to get your money back through dividends. Start-up businesses rarely pay these.

4 – Don’t put all your eggs in one basket

• Putting all your money into a single business or type of investment for example, is risky. Spreading your money across different investments makes you less dependent on any one to do well.

• A good rule of thumb is not to invest more than 10% of your money in high-risk investments (https://www.fca.org.uk/investsmart/5-questions-ask-you-invest)

5 – The value of your investment can be reduced

• The percentage of the business that you own will decrease if the business issues more shares. This could mean that the value of your investment reduces, depending on how much the business grows. Most start-up businesses issue multiple rounds of shares.

• These new shares could have addition rights that your shares don’t have, such as the right to receive a fixed dividend, which could further reduce your chances of getting a return on your investment.

If you are interested in learning more about how to protect yourself, visit the FCA’s website here (https://www.fca.org.uk/investsmart)